Jazz's (JAZZ) Q2 Earnings Beat, New Drugs Post Robust Sales

This article was originally published on Nasdaq

Jazz Pharmaceuticals JAZZ reported adjusted earnings of $4.30 per share in the second quarter of 2022, beating the Zacks Consensus Estimate of $4.20. Earnings were up 10.3% year over year.

Responses